Related Experiment Videos
Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface
X Forns1, T Allander, P Rohwer-Nutter
1Hepatitis Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. XFORNS@clinic.ub.es
Virology
|August 11, 2000
Summary
Presenting hepatitis C virus (HCV) E2 envelope protein on cell surfaces enhances its potential as a vaccine immunogen. Truncating E2 improves its native conformation and CD81 receptor binding for better vaccine development.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Hepatitis C virus (HCV) envelope proteins are key targets for neutralizing antibodies.
- Surface-expressed E2 protein is a more effective immunogen than intracellular E2.
- Efficient presentation of E2 on the cell surface is crucial for vaccine design.
Purpose of the Study:
- To explore improved methods for presenting the HCV E2 protein on the cell surface.
- To investigate the impact of transmembrane domain replacement on E1 and E2 surface expression.
- To determine optimal truncation sites for E2 surface expression and function.
Main Methods:
- Genetic manipulation to replace transmembrane domains of E1 and E2.
- Flow cytometry (FACS) analysis to assess cell-surface protein expression and conformation.
- Binding assays to evaluate the interaction of E2 with the CD81 receptor.
Main Results:
- Replacing E2's transmembrane domain did not co-express E1 on the cell surface.
- E1 can be independently expressed on the cell surface after transmembrane domain replacement.
- Truncating E2 at amino acid 661 resulted in better native conformation and CD81 binding compared to truncation at 715.
- Deletion of the hypervariable region 1 (HVR1) did not significantly affect E2 structure or CD81 binding.
Conclusions:
- Optimized cell-surface expression strategies for HCV E2 are vital for vaccine development.
- Specific truncation of E2 enhances its conformational integrity and receptor-binding capacity.
- Further research into E2 presentation and its interaction with CD81 can guide effective HCV vaccine design.